Compass: The AIC’s monthly newsletter

NB Private Equity makes modest progress in 2023

NB Private Equity Partners says that over 2023 its NAV total return in dollars was 2.3%. A narrowing discount meant that the share price return was better (9.4% in sterling terms). However, over the first quarter of 2024 the NAV return was -1.4%, driven by declines in quoted holdings and foreign exchange headwinds. Dividends for […]

Biopharma Credit makes new $100m loan

BioPharma Credit is lending $100m to Trasus Pharmaceuticals. BioPharma Credit Investments V will lend an additional $100m alongside this. Based in the US, Tarsus is a publicly traded biopharmaceutical company with a current market capitalisation of about $1.2bn (Ticker: TARS – NASDAQ). Tarsus currently markets XDEMVY® (lotilaner ophthalmic solution), a treatment for Demodex blepharitis. XDEMVY® […]

US Solar cuts dividend as implements new tender offer

US Solar Fund is planning a fixed-price tender offer at $0.764 per share (equivalent to the 31 December 2023 NAV of $0.78 per share, less 2% for the costs of administering the tender offer). Shareholders may choose to tender for sale some or all of their shares, subject to an upper limit of $19m being […]

Nvidia bet pays off for Martin Currie Global Portfolio

Martin Currie Global Portfolio managed to beat the return on the MSCI All Country World Index over the 12 months ended 31 January 2024, returning 11.2% to the index’s 10.9%. A stable discount (the result of its zero dividend discount mechanism) meant that the return to shareholders was 11.1%. The company declared dividends totaling 4.2p […]